Bio-Rad Laboratories Inc. Class A

486.09+12.67+2.68%Vol 51.06K1Y Perf -23.49%
Feb 2nd, 2023 12:30 DELAYED
BID485.29 ASK486.89
Open481.22 Previous Close473.42
Pre-Market475.00 After-Market-
 1.58 0.33%  - -
Target Price
621.67 
Analyst Rating
Strong Buy 1.33
Potential %
28.71 
Finscreener Ranking
★★★★     52.96
Insiders Trans % 3/6/12 mo.
-/-/-100 
Value Ranking
★★★+     52.23
Insiders Value % 3/6/12 mo.
-/-/-100 
Growth Ranking
★★     44.32
Insiders Shares Cnt. % 3/6/12 mo.
-/-/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
43.39 
Earnings Rating
Buy
Market Cap14.50B 
Earnings Date
16th Feb 2023
Alpha0.01 Standard Deviation0.09
Beta0.93 

Today's Price Range

480.32486.09

52W Range

344.63670.62

5 Year PE Ratio Range

4.30288.30

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
-0.52%
1 Month
12.59%
3 Months
32.98%
6 Months
-13.60%
1 Year
-23.49%
3 Years
31.17%
5 Years
86.14%
10 Years
306.44%

TickerPriceChg.Chg.%
BIO486.0912.67002.68
AAPL149.944.50503.10
GOOG107.135.70005.62
MSFT261.008.25003.26
XOM112.50-2.2450-1.96
WFC47.320.28500.61
JNJ164.13-0.7900-0.48
FB196.640.99000.51
GE83.210.89001.08
JPM139.33-0.2584-0.19
 
ProfitabilityValueIndustryS&P 500US Markets
56.10
-278.60
-273.90
-3.40
-69.91
RevenueValueIndustryS&P 500US Markets
2.07B
83.72
8.24
6.41
Earnings HistoryEstimateReportedSurprise %
Q03 20222.592.600.39
Q02 20222.463.3837.40
Q01 20222.804.9476.43
Q04 20212.873.2111.85
Q03 20212.303.7161.30
Q02 20211.903.5486.32
Q01 20212.505.21108.40
Q04 20203.104.0129.35
Earnings Per EndEstimateRevision %Trend
12/2022 QR3.450.29Positive
12/2022 FY14.380.21Positive
3/2023 QR3.26-10.19Negative
12/2023 FY15.05-3.83Negative
Next Report Date16th Feb 2023
Estimated EPS Next Report3.45
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume51.06K
Shares Outstanding29.82K
Shares Float21.08M
Trades Count3.48K
Dollar Volume24.69M
Avg. Volume163.73K
Avg. Weekly Volume156.81K
Avg. Monthly Volume148.24K
Avg. Quarterly Volume186.14K

Bio-Rad Laboratories Inc. Class A (NYSE: BIO) stock closed at 473.42 per share at the end of the most recent trading day (a 1.27% change compared to the prior day closing price) with a volume of 163.05K shares and market capitalization of 14.50B. Is a component of S&P 500, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 8000 people. Bio-Rad Laboratories Inc. Class A CEO is Norman Schwartz.

The one-year performance of Bio-Rad Laboratories Inc. Class A stock is -23.49%, while year-to-date (YTD) performance is 12.59%. BIO stock has a five-year performance of 86.14%. Its 52-week range is between 344.63 and 670.615, which gives BIO stock a 52-week price range ratio of 43.39%

Bio-Rad Laboratories Inc. Class A currently has a PE ratio of -2.10, a price-to-book (PB) ratio of 1.48, a price-to-sale (PS) ratio of 5.09, a price to cashflow ratio of 47.80, a PEG ratio of 2.32, a ROA of -41.67%, a ROC of -47.65% and a ROE of -56.29%. The company’s profit margin is -69.91%, its EBITDA margin is -273.90%, and its revenue ttm is $2.07 Billion , which makes it $83.72 revenue per share.

Of the last four earnings reports from Bio-Rad Laboratories Inc. Class A, there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $3.45 for the next earnings report. Bio-Rad Laboratories Inc. Class A’s next earnings report date is 16th Feb 2023.

The consensus rating of Wall Street analysts for Bio-Rad Laboratories Inc. Class A is Strong Buy (1.33), with a target price of $621.67, which is +28.71% compared to the current price. The earnings rating for Bio-Rad Laboratories Inc. Class A stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Bio-Rad Laboratories Inc. Class A has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Bio-Rad Laboratories Inc. Class A has a Buy technical analysis rating based on Technical Indicators (ADX : 8.87, ATR14 : 15.05, CCI20 : 101.56, Chaikin Money Flow : 0.18, MACD : 13.22, Money Flow Index : 52.69, ROC : 4.00, RSI : 63.04, STOCH (14,3) : 72.66, STOCH RSI : 0.38, UO : 59.37, Williams %R : -27.34), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Bio-Rad Laboratories Inc. Class A in the last 12-months were: Ajit Ramalingam (Option Excercise at a value of $0), Ajit Ramalingam (Sold 897 shares of value $438 216 ), Allison Schwartz (Option Excercise at a value of $0), Andrew J. Last (Option Excercise at a value of $0), Dara Wright (Option Excercise at a value of $0), Diane Dahowski (Option Excercise at a value of $0), Ilan Daskal (Option Excercise at a value of $0), Michael Crowley (Option Excercise at a value of $0), Norman Schwartz (Option Excercise at a value of $4 212 310), Simon May (Option Excercise at a value of $0), Timothy S. Ernst (Option Excercise at a value of $0)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
2 (66.67 %)
2 (66.67 %)
2 (100.00 %)
Moderate Buy
1 (33.33 %)
1 (33.33 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.33
Strong Buy
1.33
Strong Buy
1.00

Bio-Rad Laboratories Inc. Class A

Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (60% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the United States (40% of 2020 sales), Europe (34%), and Asia (21%), with Canada and Latin America accounting for the bulk of the remaining 5%. Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.

CEO: Norman Schwartz

Telephone: +1 510 724-7000

Address: 1000 Alfred Nobel Drive, Hercules 94547, CA, US

Number of employees: 8 000

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

55%45%

Bearish Bullish

56%44%

Bearish Bullish

55%45%


News

Stocktwits